Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03713710 · ClinicalTrials.gov registry record · NA

Self-Sampling for Human Papillomavirus (HPV) Testing in African American Women - Mississippi Delta

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
335
Enrollment target

NCT03713710: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT03713710 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 335 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03713710, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
335 participants
Enrollment target

Study Summary

The purpose of this study is to examine the efficacy and costs of this patient-centered approach ("Choice" between two cervical cancer screening modalities) in adherence to cervical cancer screening as compared to the current standard of care within the public health system in Mississippi (Pap test at the local department -"Pap") among un/under-screened African American women in the Mississippi Delta using a theory-based, culturally relevant intervention implemented by Peer Health Educators (PHEs).

Primary Outcome

adherence to cerivcal cancer screening by attending the Pap testing or returning the self-collected sample for HPV testing

Interventions

  • BEHAVIORAL Choice
  • BEHAVIORAL Pap testing

Trial Details

FieldValue
Enrollment Target 335 participants
Start Date 2016-11-28
Est. Completion 2019-12-31
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT03713710 record still lists

NCT03713710 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 2 interventions - of which Choice is the first listed.

NCT03713710 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03713710 about?

NCT03713710 is a clinical study titled "Self-Sampling for Human Papillomavirus (HPV) Testing in African American Women - Mississippi Delta". The purpose of this study is to examine the efficacy and costs of this patient-centered approach ("Choice" between two cervical cancer screening modalities) in adherence to cervical cancer screening as compared to the current standard of care within the public health system in Mississippi (Pap test ...

What is the current status of trial NCT03713710?

This trial is currently completed. It is a NA study. The enrollment target is 335 participants. The study started on 2016-11-28. Estimated completion is 2019-12-31.

What interventions are being tested in trial NCT03713710?

The interventions under investigation include: Choice (BEHAVIORAL), Pap testing (BEHAVIORAL).

Who is sponsoring clinical trial NCT03713710?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03713710's enrollment target sits among peer trials

335 305th of 2000 higher than 1,696 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04134754 · 335 participants · NA

    Carbon Dioxide (CO2) Chemosensitivity and SUDEP

  • NCT05554406 · 335 participants · Phase 2

    Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • NCT06183437 · 335 participants · Phase 4

    The STOP-MED CTRCD Trial

  • NCT06885177 · 335 participants · NA

    TECTONIC CAD IVL IDE Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03713710, the US trial registry maintained by the National Library of Medicine. NCT03713710 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.